Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought this was interesting,
Out take from this article.
In February 2024, Democrats from the US House Oversight Committee sent letters to Teva (Tel Aviv, Israel), Pfizer (New York, US), and Sandoz (Zug, Switzerland) to ask why several of their drugs are in short supply.
The letters refer to Teva’s shortage of Adderall, Sandoz’s amoxicillin, and Pfizer’s (along with its subsidiaries’) production of common cancer drugs, including cisplatin, carboplatin, and methotrexate.
https://www.pharmaceutical-technology.com/analyst-comment/cheap-drugs-inspections-future-war-europe-drug-shortages/?cf-view
Merci Nas 😎🙏
Welcome back !
Forget Japan. Adderall is illegal, but Vyvanse is OK, by script. of course, because Takeda makes it.
As for the UK, I bet they would streamline the paperwork, it's in high demand.
Need to submit approvals for all our drugs in Europe and Japan
Looks like Kirko needs to visit the UK.
https://www.nottsapc.nhs.uk/media/vwxjkaxa/adhd-medicines-supply-advice.pdf
the shortage is all over Europe
Oops !!!, take that one off the hype and hope list.
How far will this sink now, I wonder if the "RAT"
knew about this ??
Possible sell off sooner than expected.
Oh well......penny stocks, never can tell.
Have a great week end.
I'm here for you.....
Back in New York
Pe ratio below 7 !!!!
Time to load up
Agree 100%. Was surprised to see this wording used from asst deputy at DEA. I think there are some similarities to opioid crisis, but drastically different in many ways too. I think 600K died from opioid crisis alone. Adderall pills bought online are perceived as Adderall, but may be fentanyl or other drugs. There is the perception of an Adderall crisis that I think Nasrat will want to navigate around and sell the company sooner rather than later as this can have a negative impact in risks for DCF analysis & buyout amount.
The fact that the stimulant issue is ongoing after many months and Vyvanse supply can’t be rectified is just really sad. Hoping this buys us time for Elite’s eventual approval in ‘24 or ‘25.
I doubt it will be 'like' the opioid crisis. Are people ODing, losing their jobs?, using all their money to buy the drug?, stealing?, does it lead to heroin use, once they start a dose does that amount stop working and they have to take more and more to get the same effect?
I wouldn't even compare it to alcohol. Someone on alcohol is a PITA and if driving, dangerous to others. Someone on adderall maybe more productive and focused....horrifying!!
Kind of stupid to compare the two if you ask me.
Multiple buy orders from me coming in around 10 cents from multiple accounts. I’ll probably put in a total request of 1 to 2 million shares. Let’s see if these monkeys can really do anything or if they are all talk. So far, it’s been all talk….
I’m going out to celebrate what We have here.
Enjoy the calm before the CC.
GLTA
The goat boiler room can’t bring anything to the table.
They are backed up against a wall by this:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__18. Generate revenues over $20 million/quarter
__19. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__20. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__21. European distribution - Dexcel partnership approval by Israeli Health
__22. Full ownership of Adderall IR $ 335 Million
__23. Full ownership of Adderall XR $ 1.56 Billion
__24. Generic Concerta- $1.2 BILLION FDA submission
__25. $100 million in yearly revenue
__26. Generic Vyvanse Approval and Launch
__27. $200 million in yearly revenue
__28. Deep pocket partner for SequestOx
__29. Patented Unique ADF (w/o naltrexone)-- NDA
__30. Mikah ANDA (s)
__31. Undisclosed ANDAs/NDAs
__32. DollarLand PPS
__33. Uplist to the NASDAQ Exchange
__34. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__35. Vegas Baby !!!!!!!
X 36. PE below 8.
We got to get Nasrat paid for all those shares he has.
Is there any other way to liquidate them?
An extra penny won’t matter much to me a buyout.
Good Luck
I will be buying where ever we are, till next CC.
Dipped under 13 wow...
Picked up those .128 shares at the end of the day :)
Gap schmap. Someone wanted to sell for .13 cents. Be patient and you may be able to steal more cheapies. Total volume Mon- Thurs only 832k shares, less than 1/2 the daily volume last month. Smart players sitting on the sideline. For all we know the seller may have had a margin call and needed the cash to meet it.
It's just posting by the Board 🤡, he don't know nothing about a "buyout" ...................
Look at the 🃏's post history on Elite over the past 13 years, nothing but nonsense,
IB_🤴🏻
You post as if a buy out is guaranteed,
Who said a buy out is guaranteed ??
Read the transcript from the greatest CC ever, lol
The "Rat" never said, yes there is a buy out.
Sorry, this thing may see 12 pennies per share by EOD
I'm here for you, but keep it real....please
I may buy a few more at $0.117 !!!!!!!!!!!!!
Best Regards,
IB_🤴🏻
Really respect this post. I can feel the years of wisdom. But, perhaps you’ll allow me an edit? Your statement implies an Adam Smith equilibrium. A perfect balance of yays and nays.
If we stipulated that a group was intentionally agitating this stock to push it down, then you would still see the equilibrium we have here, but imagine a resistance band. The agitator’s have balanced against the yay’s who agave a stiffer backbone.
In this scenario, we would absolutely be undervalued even in this moment of equilibrium.
That's right Board 🤡, you hyped Elite and mislead new investors from $0.97 to $0.02 !!!!!!!!!!!!!!!!!!!!!!
Is ELTP traded in Thailand,
IB_🤴🏻
How excited will you be if Elite post blow out earnings on "June 19th" ?????????????????????
Double Great Day, right ????????????????????
LoL LoL,
IB_🤴🏻
We will see who does the best at BuyOut
At least I did not cry and whine from $0.97 to $0.02 and up to $0.15.
ELTP Locked $$ Loaded
I’ve already got millions of shares at a nickel. They have none.
The 🃏 wasn't being serious .................
The 🤡 has been posting nonsense like this for 13+ years,
IB_🤴🏻
Perhaps in an ideal world. We’re still working on getting a couple small teeny drugs past CRLs. Realistically larger drugs won’t get approved in ‘24.
He hasn’t been right for 10 years !!!!
I hope you’re right. I wouldn’t have came back if it wasn’t for revenue, profits, positive cash flow and lots of potential in the pipeline.
$5.1 Billion Market drug approval end of year. Approx buyout in 22 months.
New facility will be ready To Rock and Roll !!!!!!!!!!!!!
Im feelin' it !!
ELTP
Glad I did not listen to you at 2 cents.
Feed That Goat
You’re right and you should absolutely do what you want with your money. Asking because we had a significant drop from.21. If I was one of the peasants and it did drop to .10, I would next claim that I’m dropping it to a nickel and so forth, so one would never really get an opportunity to buy.
Oh...so now it's really supposed to get real.
Not the countless times prior when it was about to get real....got it, thanks, I'll mark this one on the calender.
" between now and the next CC"
I'm here for you,
Great response
15% = $1,500,000,000 Kirkov is the WildCard
Its about To Get Real !!!!!!!!!!!! Between now and the next CC.
ELTP
The last thing professionals want to see from a company are things like "If we only capture 5% of this market...blah blah blah"
Elite just added a new jop opening
https://www.indeed.com/cmp/Elite-Pharmaceuticals,-Inc.-1/jobs
For the new facility
Elite will be first to market Generic OxyContin
$720 MILLION Market
This will blow this stock upward.
Locked and Loaded not chasing
GLTA
$10 bILLION combined IMS markets.
5% = $$ 500,000,000
7.5% = $$$$750,000,000
10% = $$$$$$1,000,000,000
Agree 100% as we painfully await the dry spell until 10K release end of June. What is a bit frustrating is that we don’t even have news/approvals for the smaller drugs and are kept in the dark. Looking forward to seeing first full Q with Prasco partnership for Q4 to get a taste of the financial benefit.
Good morning Namtae, low volume means very few want to trade this stock at the moment. Both shareholders and those short the stock are satisfied with their positions. As you know the price is based on supply and demand. Currently there is very little of either.
In the meantime cut and paste more pics of exotic autos, that will really convince every one on a penny stock MB that you're a big deal.
LOFL stop with the BS......OMG
Don't forget I'm here for you
Good morning James.
Curious why recent low volume equates to shareholders being happy with their ELTP positions
In a vacuum, low volume could suggest lack of sellers or lack of buyers.
Does your theory suggest shareholders were unhappy with their positions when ELTP fell from appx 21 cents to 13 on more active volume?
Does the 13 cent price coupled with low volume also suggest ELTP is now trading at fair value?
Followers
|
1066
|
Posters
|
|
Posts (Today)
|
119
|
Posts (Total)
|
415136
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators mrwrn2010 NASDAQ2020 IB_ namtae |
Senior Moderator: IB_
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 85,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite Dexcel |
Adderall XR | 1.56 B | On Market | 10 | Elite Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 47 M | On Market | 5 | Elite |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 63.4M | On Market | 8 | Elite |
Percocet | 500 M | Approved in Launch Queue | 14 | ---------- |
Norco | 477 M | Approved in Launch Queue | 12 | ---------- |
Methadone | 30 M | Approved in Launch Queue | 8 | ---------- |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | 4 | ---------- |
Vyvanse | $4.30 B | Approved in Launch Queue | 11 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 8 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
2025 Q-1 | 18,803,000 | +109.39% | 3,864,056 | +144.00% |
2025 Q-2 | 18,880,000 | +33.00% | 3,500,000 | +84.00% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |